BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37309394)

  • 1. Real-World Experience of Treating Chronic Obstructive Pulmonary Disease with Triple Therapy.
    Liao KM; Wang JJ; Ho CH
    Int J Chron Obstruct Pulmon Dis; 2023; 18():1057-1066. PubMed ID: 37309394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study.
    Evans KA; Pollack M; Portillo E; Strange C; Touchette DR; Staresinic A; Patel S; Tkacz J; Feigler N
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1366-1377. PubMed ID: 36427341
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
    Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Kew KM; Mavergames C; Walters JA
    Cochrane Database Syst Rev; 2013 Oct; (10):CD010177. PubMed ID: 24127118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple Therapy versus Dual or Monotherapy with Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis.
    Mammen MJ; Lloyd DR; Kumar S; Ahmed AS; Pai V; Kunadharaju R; Gupta S; Nici L; Aaron SD; Alexander PE
    Ann Am Thorac Soc; 2020 Oct; 17(10):1308-1318. PubMed ID: 32692253
    [No Abstract]   [Full Text] [Related]  

  • 7. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality.
    Suissa S; Dell'Aniello S; Ernst P
    COPD; 2022 Dec; 19(1):1-9. PubMed ID: 34544314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid.
    Miravitlles M; Verhamme K; Calverley PMA; Dreher M; Bayer V; Gardev A; de la Hoz A; Wedzicha J; Price D
    Int J Chron Obstruct Pulmon Dis; 2022; 17():545-558. PubMed ID: 35309285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
    Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRIMUS - Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation.
    Tkacz J; Evans KA; Touchette DR; Portillo E; Strange C; Staresinic A; Feigler N; Patel S; Pollack M
    Int J Chron Obstruct Pulmon Dis; 2022; 17():329-342. PubMed ID: 35177901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other long-term condition: a mixed methods review.
    Dennett EJ; Janjua S; Stovold E; Harrison SL; McDonnell MJ; Holland AE
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013384. PubMed ID: 34309831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study.
    Buhl R; Criée CP; Kardos P; Vogelmeier CF; Kostikas K; Lossi NS; Worth H
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2557-2568. PubMed ID: 30197512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-Life Clinical and Functional Effects of Fluticasone Furoate/Umeclidinium/Vilanterol-Combined Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease.
    Pelaia C; Procopio G; Deodato MR; Florio O; Maglio A; Sciacqua A; Vatrella A; Pelaia G
    Respiration; 2021; 100(2):127-134. PubMed ID: 33302284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline.
    Nici L; Mammen MJ; Charbek E; Alexander PE; Au DH; Boyd CM; Criner GJ; Donaldson GC; Dreher M; Fan VS; Gershon AS; Han MK; Krishnan JA; Martinez FJ; Meek PM; Morgan M; Polkey MI; Puhan MA; Sadatsafavi M; Sin DD; Washko GR; Wedzicha JA; Aaron SD
    Am J Respir Crit Care Med; 2020 May; 201(9):e56-e69. PubMed ID: 32283960
    [No Abstract]   [Full Text] [Related]  

  • 18. Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease.
    Pollok J; van Agteren JE; Esterman AJ; Carson-Chahhoud KV
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012347. PubMed ID: 30838649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD 'real world' study.
    Vogelmeier CF; Worth H; Buhl R; Criée CP; Gückel E; Kardos P
    Respir Res; 2022 May; 23(1):109. PubMed ID: 35501806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.
    Martinez FJ; Rabe KF; Ferguson GT; Wedzicha JA; Singh D; Wang C; Rossman K; St Rose E; Trivedi R; Ballal S; Darken P; Aurivillius M; Reisner C; Dorinsky P
    Am J Respir Crit Care Med; 2021 Mar; 203(5):553-564. PubMed ID: 33252985
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.